Time to Consider Initiating SGLT2 Inhibitors and/or GLP-1RAs in the Inpatient Cardiovascular Care Setting—And Here’s How
In this medfyle
Expert commentary by Vanita R. Aroda, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2021 - 81st Scientific Sessions and presented by:
Sandeep Das, MD, MPH
University of Texas Southwestern Medical Center
Dallas, TX, USA
The content is produced by Infomedica, the official reporting partner of ADA 2021.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Vanita R. Aroda, MD
Brigham and Women's Hospital, Boston, MA
About the Expert
Vanita R. Aroda, MD
Brigham and Women's Hospital, Boston, MA
Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is Member of the Faculty of Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes, and Metabolism at the University of California San Diego, CA, USA.
Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multi-center clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for multiple therapeutic clinical trials. Dr. Aroda serves on the Professional Practice Committee of the American Diabetes Association.
Disclosures:
Consultant (self): Applied Therapeutics, Duke, Novo Nordisk, Pfizer, Sanofi
Employee: Janssen (spouse)
Research Support (institutional contracts): Applied Therapeutics/Medpace; Eli Lilly; Premier/Fractyl, Novo Nordisk, Sanofi/Medpace
References
1. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396(10254):819–29.
2. Heerspink HJL, StefánssonBV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383(15):1436–46.
3. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7(11):845–54.
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989.
5. Nargesi AA, et al. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. J Am Heart Assoc 2021;e021084.
6. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med;365(22):2088–97.
